Driving reinvestment in R&D for antibiotics and advocating their responsible use

R&D for Antibiotic Resistance & Infectious Diseases in China Supported by GSK

GlaxoSmithKline (GSK) will put up $29 million for a Beijing-based R&D institute to tackle antibiotic resistance and infectious disease health threats in China by working in tandem with academics and regulators. The Institute for Infectious Diseases and Public Health will draw on 20 in-house GSK researchers to start and will look to existing drugs in the U.K. drugmaker’s portfolio as well as clinical trial stage work on HIV and multidrug-resistant bacterial infections, China Daily reported.


Click here to read the full story.